Effect of High-Intensity Treadmill Exercise on Motor Symptoms in Patients With De Novo Parkinson Disease: A Phase 2 Randomized Clinical Trial
- PMID: 29228079
- PMCID: PMC5838616
- DOI: 10.1001/jamaneurol.2017.3517
Effect of High-Intensity Treadmill Exercise on Motor Symptoms in Patients With De Novo Parkinson Disease: A Phase 2 Randomized Clinical Trial
Abstract
Importance: Parkinson disease is a progressive neurologic disorder. Limited evidence suggests endurance exercise modifies disease severity, particularly high-intensity exercise.
Objectives: To examine the feasibility and safety of high-intensity treadmill exercise in patients with de novo Parkinson disease who are not taking medication and whether the effect on motor symptoms warrants a phase 3 trial.
Design, setting, and participants: The Study in Parkinson Disease of Exercise (SPARX) was a phase 2, multicenter randomized clinical trial with 3 groups and masked assessors. Individuals from outpatient and community-based clinics were enrolled from May 1, 2012, through November 30, 2015, with the primary end point at 6 months. Individuals with idiopathic Parkinson disease (Hoehn and Yahr stages 1 or 2) aged 40 to 80 years within 5 years of diagnosis who were not exercising at moderate intensity greater than 3 times per week and not expected to need dopaminergic medication within 6 months participated in this study. A total of 384 volunteers were screened by telephone; 128 were randomly assigned to 1 of 3 groups (high-intensity exercise, moderate-intensity exercise, or control).
Interventions: High-intensity treadmill exercise (4 days per week, 80%-85% maximum heart rate [n = 43]), moderate-intensity treadmill exercise (4 days per week, 60%-65% maximum heart rate [n = 45]), or wait-list control (n = 40) for 6 months.
Main outcomes and measures: Feasibility measures were adherence to prescribed heart rate and exercise frequency of 3 days per week and safety. The clinical outcome was 6-month change in Unified Parkinson's Disease Rating Scale motor score.
Results: A total of 128 patients were included in the study (mean [SD] age, 64 [9] years; age range, 40-80 years; 73 [57.0%] male; and 108 [84.4%] non-Hispanic white). Exercise rates were 2.8 (95% CI, 2.4-3.2) days per week at 80.2% (95% CI, 78.8%-81.7%) maximum heart rate in the high-intensity group and 3.2 (95% CI, 2.8-3.6; P = .13) days per week at 65.9% (95% CI, 64.2%-67.7%) maximum heart rate in the moderate-intensity group (P < .001). The mean change in Unified Parkinson's Disease Rating Scale motor score in the high-intensity group was 0.3 (95% CI, -1.7 to 2.3) compared with 3.2 (95% CI, 1.4 to 5.1) in the usual care group (P = .03). The high-intensity group, but not the moderate-intensity group, reached the predefined nonfutility threshold compared with the control group. Anticipated adverse musculoskeletal events were not severe.
Conclusions and relevance: High-intensity treadmill exercise may be feasible and prescribed safely for patients with Parkinson disease. An efficacy trial is warranted to determine whether high-intensity treadmill exercise produces meaningful clinical benefits in de novo Parkinson disease.
Trial registration: clinicaltrials.gov Identifier: NCT01506479.
Conflict of interest statement
Figures
![Figure 1.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/5838616/bin/jamaneurol-75-219-g001.gif)
![Figure 2.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/5838616/bin/jamaneurol-75-219-g002.gif)
Similar articles
-
Study in Parkinson's disease of exercise phase 3 (SPARX3): study protocol for a randomized controlled trial.Trials. 2022 Oct 6;23(1):855. doi: 10.1186/s13063-022-06703-0. Trials. 2022. PMID: 36203214 Free PMC article.
-
Effectiveness of home-based and remotely supervised aerobic exercise in Parkinson's disease: a double-blind, randomised controlled trial.Lancet Neurol. 2019 Nov;18(11):998-1008. doi: 10.1016/S1474-4422(19)30285-6. Epub 2019 Sep 11. Lancet Neurol. 2019. PMID: 31521532 Clinical Trial.
-
Physical Activity in De Novo Parkinson Disease: Daily Step Recommendation and Effects of Treadmill Exercise on Physical Activity.Phys Ther. 2021 Oct 1;101(10):pzab174. doi: 10.1093/ptj/pzab174. Phys Ther. 2021. PMID: 34244805 Clinical Trial.
-
Treadmill training for patients with Parkinson Disease. An abridged version of a Cochrane Review.Eur J Phys Rehabil Med. 2016 Oct;52(5):704-713. Epub 2016 Mar 4. Eur J Phys Rehabil Med. 2016. PMID: 26940123 Review.
-
Novel Augmentation Strategies in Major Depression.Dan Med J. 2017 Apr;64(4):B5338. Dan Med J. 2017. PMID: 28385173 Review.
Cited by
-
The rise of Parkinson's disease is a global challenge, but efforts to tackle this must begin at a national level: a protocol for national digital screening and "eat, move, sleep" lifestyle interventions to prevent or slow the rise of non-communicable diseases in Thailand.Front Neurol. 2024 May 13;15:1386608. doi: 10.3389/fneur.2024.1386608. eCollection 2024. Front Neurol. 2024. PMID: 38803644 Free PMC article.
-
Aerobic exercise improves motor dysfunction in Parkinson's model mice via differential regulation of striatal medium spiny neuron.Sci Rep. 2024 May 27;14(1):12132. doi: 10.1038/s41598-024-63045-4. Sci Rep. 2024. PMID: 38802497 Free PMC article.
-
[Multidisciplinary Complex Treatment of Parkinson's disease : Cornerstone of an individualized treatment].Nervenarzt. 2024 May 16. doi: 10.1007/s00115-024-01666-w. Online ahead of print. Nervenarzt. 2024. PMID: 38755423 Review. German.
-
The Contribution of Type 2 Diabetes to Parkinson's Disease Aetiology.Int J Mol Sci. 2024 Apr 15;25(8):4358. doi: 10.3390/ijms25084358. Int J Mol Sci. 2024. PMID: 38673943 Free PMC article. Review.
-
Epidemiology of Parkinson's Disease: An Update.Curr Neurol Neurosci Rep. 2024 Jun;24(6):163-179. doi: 10.1007/s11910-024-01339-w. Epub 2024 Apr 20. Curr Neurol Neurosci Rep. 2024. PMID: 38642225 Review.
References
-
- Kalia LV, Lang AE. Parkinson’s disease. Lancet. 2015;386(9996):896-912. - PubMed
-
- Shulman LM, Gruber-Baldini AL, Anderson KE, et al. . The evolution of disability in Parkinson disease. Mov Disord. 2008;23(6):790-796. - PubMed
-
- Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA. 2014;311(16):1670-1683. - PubMed
-
- Smith AD, Zigmond MJ. Can the brain be protected through exercise? lessons from an animal model of parkinsonism. Exp Neurol. 2003;184(1):31-39. - PubMed
-
- Zigmond MJ, Smeyne RJ. Exercise: is it a neuroprotective and if so, how does it work? Parkinsonism Relat Disord. 2014;20(suppl 1):S123-S127. - PubMed
Publication types
MeSH terms
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical